Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.63 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.56 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.49 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.49 |
| ▸ | CASP6 | P55212 | 1/20 | 0.49 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.49 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5270784 | 0.88 | NOTUM (0.63) | NOTUMPDE3BPDE3ALMNAKMT2A | |
| SCHEMBL1855164 | 0.86 | LMNA (0.52) | NOTUMPDE3BPDE3ALMNAPOLB | |
| SCHEMBL5533649 | 0.83 | NOTUM (0.65) | NOTUMPDE3BPDE3AKMT2APOLB | |
| SCHEMBL10274847 | 0.83 | NOTUM (0.65) | NOTUMPDE3BPDE3ALMNAKMT2A | |
| SCHEMBL395823 | 0.82 | NOTUM (0.63) | NOTUMPDE3BPDE3AKMT2APOLB | |
| SCHEMBL302938 | 0.81 | LMNA (0.48) | NOTUMPDE3BPDE3ALMNA | |
| SCHEMBL31286980 | 0.81 | LMNA (0.48) | NOTUMPDE3BPDE3ALMNAKMT2A | |
| SCHEMBL30375885 | 0.81 | LMNA (0.48) | NOTUMPDE3BPDE3ALMNA | |
| Hydrochloric Acid SCHEMBL398436 | 0.81 | NOTUM (0.61) | NOTUMPDE3BPDE3AKMT2APOLB | |
| SCHEMBL18737439 | 0.79 | NOTUM (0.60) | NOTUMPDE3BPDE3ALMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3704105-B9 | ANTIBACTERIAL COMPOUNDS | DISCUVA LTD (GB) | 2025-03-05 | — | — | EP | disclosed |
| EP-3704105-B1 | ANTIBACTERIAL COMPOUNDS | DISCUVA LTD (GB) | 2024-10-16 | — | — | EP | disclosed |
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| EP-4223754-A1 | COMPOUND AS AKT KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-08-09 | — | — | EP | disclosed |
| CN-111566099-B | Antibacterial compounds | 迪斯库瓦有限公司 | 2023-06-02 | — | — | CN | disclosed |
| US-20220372027-A1 | ANTIBACTERIAL COMPOUNDS | DISCUVA LTD. (GB) | 2022-11-24 | — | — | US | disclosed |
| US-11345694-B2 | Antibacterial compounds | DISCUVA LTD. (GB) | 2022-05-31 | — | — | US | disclosed |
| US-11345694-B2 | Antibacterial compounds | DISCUVA LTD. (GB) | 2022-05-31 | — | — | US | disclosed |
| US-20210163460-A1 | ANTIBACTERIAL COMPOUNDS | DISCUVA LTD. (GB) | 2021-06-03 | — | — | US | disclosed |
| US-20210163460-A1 | ANTIBACTERIAL COMPOUNDS | DISCUVA LTD. (GB) | 2021-06-03 | — | — | US | disclosed |
| US-8114893-B2 | Compounds and methods of use | GENENTECH, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-8114893-B2 | Compounds and methods of use | GENENTECH, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20100190782-A1 | COMPOUNDS AND METHODS OF USE | ABBVIE INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100190782-A1 | COMPOUNDS AND METHODS OF USE | ABBVIE INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100190782-A1 | COMPOUNDS AND METHODS OF USE | ABBVIE INC. | 2010-07-29 | — | — | US | disclosed |
| WO-2010080478-A1 | COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| US-7312209-B2 | Acridone inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| US-20050165011-A1 | Benzoxazine and benzoxazinone substituted triazoles | GELLIBERT FRANCOISE J (FR) | 2005-07-28 | — | — | US | disclosed |
| EP-1506191-A1 | BENZOXAZINE AND BENZOXAZINONE SUBSTITUTED TRIAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-16 | — | — | EP | disclosed |
| WO-2003097639-A1 | BENZOXAZINE AND BENZOXAZINONE SUBSTITUTED TRIAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345694-B2 | Antibacterial compounds | CFTR, MRPL21, NQO1 | NOTUM 2254/4885PDE3B 719/4885PDE3A 1268/4885 |
| US-20050165011-A1 | Benzoxazine and benzoxazinone substituted triazoles | ACVR1, TGFBR1, SMAD3 | NOTUM 3577/4885PDE3B 1687/4885PDE3A 1698/4885 |
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | AKT2, MTOR, AKT1 | NOTUM 301/4885PDE3B 1238/4885PDE3A 1539/4885 |
| US-20220372027-A1 | ANTIBACTERIAL COMPOUNDS | MRPL21, NRDC, PGLS | NOTUM 2780/4885PDE3B 2244/4885PDE3A 2983/4885 |
| US-20210163460-A1 | ANTIBACTERIAL COMPOUNDS | CFTR, MRPL21, NQO1 | NOTUM 2254/4885PDE3B 719/4885PDE3A 1268/4885 |
| US-20100190782-A1 | COMPOUNDS AND METHODS OF USE | BCL2A1, BCL2, BAX | NOTUM 4716/4885PDE3B 1165/4885PDE3A 2663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.